Radiosensitization of IDH-Mutated Gliomas through ZMYND8 – a Pathway to Improved Outcomes-Reference-Cited by-同舟云学术

Radiosensitization of IDH-Mutated Gliomas through ZMYND8 – a Pathway to Improved Outcomes

Published:2023-02-24 Issue:9 Volume:29 Page:1648-1650
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Sachdev Sean¹²^ORCID,Dmello Crismita²³^ORCID,Sonabend Adam M.²³^ORCID

Affiliation:

1. 1Department of Radiation Oncology, Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

2. 2Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

3. 3Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Abstract

SummaryIsocitrate dehydrogenase 1–mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes.See related article by Carney et al., p. 1763

Funder

National Cancer Institute

National Institute of Neurological Disorders and Stroke

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-0018/3277033/ccr-23-0018.pdf

Reference20 articles.

1. Zinc finger MYND-type containing 8 (ZMYND8) is epigenetically regulated in mutant isocitrate dehydrogenase 1 (IDH1) glioma to promote radioresistance;Carney;Clin Cancer Res,2023

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH;Cairncross;J Clin Oncol,2014

4. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design;Jaeckle;Neuro Oncol,2021

5. Indications for treatment: is observation or chemotherapy alone a reasonable approach in the management of low-grade gliomas?;Schaff;Semin Radiat Oncol,2015